Matt vs Myeloma : 49
4.6
$ 7.00
In stock
(790)
Product Description
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial - eClinicalMedicine
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial - The Lancet Haematology
Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma - Biology of Blood and Marrow Transplantation
CS1 Targeted Chimeric Antigen Receptors (CAR) for Treatment of Multiple Myeloma - Biology of Blood and Marrow Transplantation
Cancers, Free Full-Text
CAR T-cell therapy for patients with multiple myeloma
Cancers, Free Full-Text
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
CAR T-cell therapy for patients with multiple myeloma
Personalizing Options for Relapse/Refractory Patients
Matt vs Myeloma
Maintenance Therapy after Transplant: Multiple Myeloma
